Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma

Xue Song, Zhimei Liu, Katherine Cappell, Christopher Gregory, Qayyim Said, Judith Prestifilippo, Hearns Charles, John Hulbert, John Bissler

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To quantify healthcare utilization and costs in patients with tuberous sclerosis complex (TSC) and renal angiomyolipoma (AML) in a matched cohort of patients without TSC or AML. Methods: Administrative data from the MarketScan Research Databases were used to select patients with TSC and renal AML during January 1, 2000–March 31, 2013 from the Commercial database and January 1, 2000–June 30, 2012 from the Medicaid database. Patients were required to have at least 30 days of follow-up from initiation into the study, and were followed until inpatient death, end of insurance coverage, or the end of study. Age, calendar year, and payer-matched controls that had no TSC and no AML were selected. All-cause annualized healthcare utilization and costs were calculated by service category. Results: A total of 218 patients under 18 years and 377 patients 18 years and older with TSC-renal AML were selected from the Commercial database, and matched to 654 and 1,131 controls, respectively. Thirty-eight patients under 18 years and 110 patients 18 years or older with TSC-renal AML were selected from the Medicaid database, and matched to 54 and 212 controls, respectively. Within the Commercial cohort, and across both age groups, TSC-renal AML patients utilized more healthcare services than their matched controls. Within the Medicaid cohort, in both age groups, utilization was higher in TSC-renal AML patients vs control patients for inpatient admissions, emergency room visits, physician office visits, and hospital-based outpatient visits. Across age groups and in both the Commercial and Medicaid cohorts, the annual average total costs were significantly higher in TSC-renal AML patients compared to control patients (p < 0.05 for all). Healthcare costs ranged from $29,240–$48,499 for TSC-renal AML patients and from $2,082–$10,864 for control patients. Conclusions: Compared to controls, TSC-renal AML patients incurred substantially higher annual healthcare utilization and costs.

Original languageEnglish (US)
Pages (from-to)388-394
Number of pages7
JournalJournal of Medical Economics
Volume20
Issue number4
DOIs
StatePublished - Apr 3 2017

Fingerprint

Angiomyolipoma
Health Care Costs
Tuberous Sclerosis
Kidney
Medicaid
Databases
Age Groups
Inpatients
Office Visits
Physicians' Offices
Insurance Coverage
Patient Admission

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma. / Song, Xue; Liu, Zhimei; Cappell, Katherine; Gregory, Christopher; Said, Qayyim; Prestifilippo, Judith; Charles, Hearns; Hulbert, John; Bissler, John.

In: Journal of Medical Economics, Vol. 20, No. 4, 03.04.2017, p. 388-394.

Research output: Contribution to journalArticle

Song, X, Liu, Z, Cappell, K, Gregory, C, Said, Q, Prestifilippo, J, Charles, H, Hulbert, J & Bissler, J 2017, 'Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma', Journal of Medical Economics, vol. 20, no. 4, pp. 388-394. https://doi.org/10.1080/13696998.2016.1272461
Song, Xue ; Liu, Zhimei ; Cappell, Katherine ; Gregory, Christopher ; Said, Qayyim ; Prestifilippo, Judith ; Charles, Hearns ; Hulbert, John ; Bissler, John. / Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma. In: Journal of Medical Economics. 2017 ; Vol. 20, No. 4. pp. 388-394.
@article{99e3326327bb48af9cd55d359df75af0,
title = "Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma",
abstract = "Objective: To quantify healthcare utilization and costs in patients with tuberous sclerosis complex (TSC) and renal angiomyolipoma (AML) in a matched cohort of patients without TSC or AML. Methods: Administrative data from the MarketScan Research Databases were used to select patients with TSC and renal AML during January 1, 2000–March 31, 2013 from the Commercial database and January 1, 2000–June 30, 2012 from the Medicaid database. Patients were required to have at least 30 days of follow-up from initiation into the study, and were followed until inpatient death, end of insurance coverage, or the end of study. Age, calendar year, and payer-matched controls that had no TSC and no AML were selected. All-cause annualized healthcare utilization and costs were calculated by service category. Results: A total of 218 patients under 18 years and 377 patients 18 years and older with TSC-renal AML were selected from the Commercial database, and matched to 654 and 1,131 controls, respectively. Thirty-eight patients under 18 years and 110 patients 18 years or older with TSC-renal AML were selected from the Medicaid database, and matched to 54 and 212 controls, respectively. Within the Commercial cohort, and across both age groups, TSC-renal AML patients utilized more healthcare services than their matched controls. Within the Medicaid cohort, in both age groups, utilization was higher in TSC-renal AML patients vs control patients for inpatient admissions, emergency room visits, physician office visits, and hospital-based outpatient visits. Across age groups and in both the Commercial and Medicaid cohorts, the annual average total costs were significantly higher in TSC-renal AML patients compared to control patients (p < 0.05 for all). Healthcare costs ranged from $29,240–$48,499 for TSC-renal AML patients and from $2,082–$10,864 for control patients. Conclusions: Compared to controls, TSC-renal AML patients incurred substantially higher annual healthcare utilization and costs.",
author = "Xue Song and Zhimei Liu and Katherine Cappell and Christopher Gregory and Qayyim Said and Judith Prestifilippo and Hearns Charles and John Hulbert and John Bissler",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/13696998.2016.1272461",
language = "English (US)",
volume = "20",
pages = "388--394",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma

AU - Song, Xue

AU - Liu, Zhimei

AU - Cappell, Katherine

AU - Gregory, Christopher

AU - Said, Qayyim

AU - Prestifilippo, Judith

AU - Charles, Hearns

AU - Hulbert, John

AU - Bissler, John

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Objective: To quantify healthcare utilization and costs in patients with tuberous sclerosis complex (TSC) and renal angiomyolipoma (AML) in a matched cohort of patients without TSC or AML. Methods: Administrative data from the MarketScan Research Databases were used to select patients with TSC and renal AML during January 1, 2000–March 31, 2013 from the Commercial database and January 1, 2000–June 30, 2012 from the Medicaid database. Patients were required to have at least 30 days of follow-up from initiation into the study, and were followed until inpatient death, end of insurance coverage, or the end of study. Age, calendar year, and payer-matched controls that had no TSC and no AML were selected. All-cause annualized healthcare utilization and costs were calculated by service category. Results: A total of 218 patients under 18 years and 377 patients 18 years and older with TSC-renal AML were selected from the Commercial database, and matched to 654 and 1,131 controls, respectively. Thirty-eight patients under 18 years and 110 patients 18 years or older with TSC-renal AML were selected from the Medicaid database, and matched to 54 and 212 controls, respectively. Within the Commercial cohort, and across both age groups, TSC-renal AML patients utilized more healthcare services than their matched controls. Within the Medicaid cohort, in both age groups, utilization was higher in TSC-renal AML patients vs control patients for inpatient admissions, emergency room visits, physician office visits, and hospital-based outpatient visits. Across age groups and in both the Commercial and Medicaid cohorts, the annual average total costs were significantly higher in TSC-renal AML patients compared to control patients (p < 0.05 for all). Healthcare costs ranged from $29,240–$48,499 for TSC-renal AML patients and from $2,082–$10,864 for control patients. Conclusions: Compared to controls, TSC-renal AML patients incurred substantially higher annual healthcare utilization and costs.

AB - Objective: To quantify healthcare utilization and costs in patients with tuberous sclerosis complex (TSC) and renal angiomyolipoma (AML) in a matched cohort of patients without TSC or AML. Methods: Administrative data from the MarketScan Research Databases were used to select patients with TSC and renal AML during January 1, 2000–March 31, 2013 from the Commercial database and January 1, 2000–June 30, 2012 from the Medicaid database. Patients were required to have at least 30 days of follow-up from initiation into the study, and were followed until inpatient death, end of insurance coverage, or the end of study. Age, calendar year, and payer-matched controls that had no TSC and no AML were selected. All-cause annualized healthcare utilization and costs were calculated by service category. Results: A total of 218 patients under 18 years and 377 patients 18 years and older with TSC-renal AML were selected from the Commercial database, and matched to 654 and 1,131 controls, respectively. Thirty-eight patients under 18 years and 110 patients 18 years or older with TSC-renal AML were selected from the Medicaid database, and matched to 54 and 212 controls, respectively. Within the Commercial cohort, and across both age groups, TSC-renal AML patients utilized more healthcare services than their matched controls. Within the Medicaid cohort, in both age groups, utilization was higher in TSC-renal AML patients vs control patients for inpatient admissions, emergency room visits, physician office visits, and hospital-based outpatient visits. Across age groups and in both the Commercial and Medicaid cohorts, the annual average total costs were significantly higher in TSC-renal AML patients compared to control patients (p < 0.05 for all). Healthcare costs ranged from $29,240–$48,499 for TSC-renal AML patients and from $2,082–$10,864 for control patients. Conclusions: Compared to controls, TSC-renal AML patients incurred substantially higher annual healthcare utilization and costs.

UR - http://www.scopus.com/inward/record.url?scp=85009802382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009802382&partnerID=8YFLogxK

U2 - 10.1080/13696998.2016.1272461

DO - 10.1080/13696998.2016.1272461

M3 - Article

VL - 20

SP - 388

EP - 394

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

IS - 4

ER -